Skip to main content

Episodes

What happens when a cannabis compassion club gets raided again despite previous Supreme Court decisions on their side, fervent public support, and years after cannabis legalization? Kirk visits Ted Smith at the Victoria Cannabis Buyers Club (VCBC) just days after its latest raid. Ted discusses ongoing legal challenges, compassionate access, Rick Simpson Oil (RSO), cannabis harm reduction, pharmacist-led patient screening, CBD drug interactions, and the future of medical cannabis in Canada. This is a thought-provoking conversation about patient care, cannabis policy, and why some Canadians still struggle to access the products they need. Listen now to learn how advocacy, healthcare, and cannabis policy continue to collide in post-legalization Canada.

 
Why is cannabis research so much harder than researching other medicines? Lauren Kelly PhD is an Associate Professor at the University of Manitoba, Cannabis researcher and Trialist, CCIC President, and CMCN Co-Lead, she joins Reefer MEDness to explain why cannabis clinical trials face unique barriers in Canada. Learn how Health Canada regulations, GMP vs GPP standards, product consistency challenges, and gaps in the Cannabis Act affect research, patient care, and evidence generation. Discover why researchers often can't study the same cannabis products patients actually use, how clinical trials begin from real-world observations, and what Canada can do to become a global leader in cannabis science. Listen now to understand the hidden challenges behind cannabis research and the future of evidence-based medical cannabis.

Can medical cannabis help children—and what does the evidence actually show? Pediatric pharmacologist, Dr. Lauren Kelly, joins Trevor and Kirk to discuss medical cannabis in children. This wide ranging conversation includes discussion about epilepsy, autism, pediatric oncology, and the unique challenges of studying cannabinoids during development. Learn what researchers know about CBD, THC & kids, why evidence remains relatively limited, and how stigma, policy, and education continue to affect patient care. Listen now for an evidence-based discussion on pediatric cannabis research, safety, and the future of cannabinoid medicine for children.

Could CBD help your dog with seizures, chronic pain, or relentless itching—and is THC really as dangerous for pets as we've been told? Trevor and Kirk sit down with Dr. Kevin Toman, a California-based veterinarian specializing in pet longevity and preventive care. Drawing on more than 40 years of veterinary experience, Dr. Kevin explains why CBD has become an important tool in his practice, particularly for managing seizures, joint pain, inflammation, and skin conditions in dogs. The conversation explores the science behind cannabinoid therapy in pets, common misconceptions about THC toxicity, the challenges veterinarians face when recommending cannabis products, and why product quality matters. Dr. Kevin also shares his perspective on modern veterinary medicine, proactive wellness strategies, and helping pets live longer, healthier lives. Whether you're a dog owner, a healthcare professional, or simply curious about veterinary cannabis medicine, this episode offers a balanced, evidence-based look at a fast growing area of pet health care. Listen and learn how cannabinoids can fit into a comprehensive wellness plan for your dog—and what every pet owner should know before choosing a CBD product.
Can full-spectrum cannabis work better than isolates — even if it tastes worse? In Part 2 with Seann Poli of JAN Rx, Trevor explores CBG, CBC, acidic cannabinoids, the entourage effect, veteran cannabis care, and why cannabis companies are increasingly filling healthcare roles traditionally held by pharmacists and nurses. Plus: a new “rocket fuel” cannabinoid blend, hormone-focused cannabis products, and the future of medical cannabis guidance in Canada.
Published in Episodes, Seann Poli, JANrx

Can medical cannabis care become more personalized and patient-focused? Trevor and Kirk talk with Seann Poli of JANrx about raising capital during the early LP boom to building a 100% Canadian, independent medical cannabis company. Seann tells us about veteran cannabis care, challenges dealing with insurance companies, CBD/CBN products, medical cannabis education, and the future of holistic cannabinoid wellness in Canada. Learn how personalized cannabis support is helping veterans manage PTSD, sleep, pain, and overall health for veterans and civilians alike.

Published in Episodes, Seann Poli, JANrx

Can medical cannabis help patients reduce opioids, sleep better, and reclaim quality of life? In Part 2 of Trevor and Kirk’s conversation with German physician Dr. Vlad Gavril, they continue to explore cannabinoid medicine in Germany. Dr. Vlad discusses chronic pain, insomnia, cannabis smoking vs vaping, opioid reduction, and the evolving German cannabis system. He shares powerful patient stories while emphasizing an honest message: cannabis can help many people — but it’s not magic, and it doesn’t work for everyone. Listen to how cannabis medicine is evolving in Europe.
A German cannabis physician, a nurse and a pharmacist walk into a bar... I mean a podcast. In this fascinating episode of Reefer MEDness, Trevor (pharmacist) and Kirk (registered nurse) sit down with Dr. Vlad Gavril, a German GP specializing in cannabinoid therapy, to explore how medical cannabis is transforming patient care in Germany. Dr. Vlad explains how Germany’s partial cannabis legalization in April 2024 dramatically changed access to medical cannabis. But with this rapid expansion comes challenges: inconsistent patient education, and stigma around cannabis. The conversation unpacks how Dr. Vlad uses cannabis clinically—from chronic pain and insomnia to depression and ADHD—and why education about cannabinoids, terpenes, and individualized treatment is critical. Dr. Vlad shares how he guides patients toward vaporization rather than smoking, explores terpene-based strain selection, and explains the importance of activating the body’s endocannabinoid system through lifestyle changes alongside cannabis therapy. This episode offers rare insight into the rapidly evolving global landscape of medical cannabis policy, patient care, and cannabinoid science. Listen now to learn how cannabis medicine is being practiced in Germany—and what Canadian clinicians and patients can learn from it.

Can a massive data project finally answer the biggest questions about medical cannabis? In Part 2 of our conversation with Dr. Johannes Thrul, we explore the National Cannabis Study, an ambitious effort to build a global repository of cannabis research and real-world patient data. From standardized tools like the Cannabis Use Questionnaire to combining datasets from multiple studies, this project aims to uncover how cannabis truly impacts conditions like chronic pain, anxiety, PTSD, and insomnia. With AI analysis, collaborative research, and a goal of 10,000 participants, the team hopes to transform fragmented cannabis studies into one powerful evidence base. Listen now to learn how this groundbreaking cannabis database could reshape the future of cannabis medicine.

 What truth can big data unlock about medical cannabis? Dr. Johannes Thrul from Johns Hopkins talks about cannabis use disorder, psychiatric risks, THC intoxication, and the groundbreaking Cannabis Health Research Initiative. The ambitious Cannabis Health Research Initiative is a groundbreaking effort to build a national medical cannabis registry and research database. Dr. Thrul shares how the National Cannabis Study will track new medical cannabis users over time, analyze biomarkers and electronic health records, and use AI to identify if medicinal cannabis is helping or not. The goal: generate real-world evidence about the benefits, risks, and clinical applications of cannabinoids—helping researchers design better clinical trials and improve patient care. Listen now to learn how real-world data may reshape the science of cannabis medicine.
Page 2 of 20